BidaskClub upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a sell rating to a hold rating in a research note issued to investors on Thursday, BidAskClub reports.
Several other equities analysts have also recently weighed in on AIMT. Roth Capital started coverage on shares of Aimmune Therapeutics in a research note on Friday, July 12th. They set a buy rating and a $45.00 target price for the company. Royal Bank of Canada cut their target price on shares of Aimmune Therapeutics to $50.00 and set an outperform rating for the company in a research note on Friday, August 9th. ValuEngine lowered shares of Aimmune Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, September 25th. Stifel Nicolaus upgraded shares of Aimmune Therapeutics to a positive rating in a research report on Monday, September 16th. Finally, Zacks Investment Research lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a research report on Tuesday, October 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $44.11.
AIMT traded down $0.34 during trading on Thursday, hitting $24.21. 757,615 shares of the company traded hands, compared to its average volume of 714,448. The company has a market cap of $1.52 billion, a PE ratio of -6.60 and a beta of -0.08. The stock’s 50-day simple moving average is $21.58 and its two-hundred day simple moving average is $20.68. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $36.12. The company has a current ratio of 5.80, a quick ratio of 5.80 and a debt-to-equity ratio of 0.24.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08). During the same quarter in the prior year, the firm earned ($0.91) EPS. Equities analysts expect that Aimmune Therapeutics will post -4 EPS for the current year.
In other Aimmune Therapeutics news, CFO Eric Bjerkholt acquired 1,550 shares of the stock in a transaction on Wednesday, September 18th. The stock was acquired at an average price of $22.57 per share, for a total transaction of $34,983.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.75% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in AIMT. Marshall Wace North America L.P. bought a new stake in shares of Aimmune Therapeutics in the 1st quarter worth about $32,000. Aperio Group LLC bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $76,000. Bank of Montreal Can lifted its holdings in shares of Aimmune Therapeutics by 336.3% in the 2nd quarter. Bank of Montreal Can now owns 4,363 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 3,363 shares during the last quarter. Quantamental Technologies LLC bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $140,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $212,000. Hedge funds and other institutional investors own 78.06% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: Do investors pay a separate front-end load every time they buy additional shares?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.